相似文献
1
Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of origin.
Pigment Cell Melanoma Res. 2012 May;25(3):395-7. doi: 10.1111/j.1755-148X.2012.00994.x.
2
A case of unknown primary melanoma detected with a BRAF gene mutation from a pleural fluid cell block.
J Dermatol. 2023 Sep;50(9):e305-e306. doi: 10.1111/1346-8138.16812. Epub 2023 Apr 23.
3
Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
Br J Cancer. 2011 Jul 12;105(2):327-8. doi: 10.1038/bjc.2011.239. Epub 2011 Jun 21.
4
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Dermatology. 2015;231(2):127-33. doi: 10.1159/000381849. Epub 2015 Jun 27.
5
Cells to Surgery Quiz: October 2015.
J Invest Dermatol. 2015 Oct;135(10):e18. doi: 10.1038/jid.2015.310.
6
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Clin Cancer Res. 2010 Jul 1;16(13):3356-67. doi: 10.1158/1078-0432.CCR-09-2509. Epub 2010 May 11.
7
Comparative genomic characterization of melanoma of known and unknown primary.
Clin Transl Oncol. 2021 Nov;23(11):2302-2308. doi: 10.1007/s12094-021-02629-2. Epub 2021 May 2.
8
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.
J Invest Dermatol. 2014 Dec;134(12):3000-3003. doi: 10.1038/jid.2014.272. Epub 2014 Jul 7.
9
A Review of Melanoma Subtypes: Genetic and Treatment Considerations.
J Surg Oncol. 2025 Mar;131(3):356-364. doi: 10.1002/jso.27953. Epub 2024 Oct 16.
10
B-RAF and melanocytic neoplasia.
J Am Acad Dermatol. 2005 Jul;53(1):108-14. doi: 10.1016/j.jaad.2005.04.013.
引用本文的文献
1
Tumor-infiltrating lymphocytes in melanoma: diagnostic and prognostic implications from biopsy to circulation.
J Liq Biopsy. 2025 Jun 28;9:100308. doi: 10.1016/j.jlb.2025.100308. eCollection 2025 Sep.
2
Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening.
Cancer Res Commun. 2025 Jul 1;5(7):1102-1118. doi: 10.1158/2767-9764.CRC-24-0416.
3
NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma.
Cancer Res. 2025 Jun 10. doi: 10.1158/0008-5472.CAN-24-3904.
4
An epigenetic switch controls an alternative NR2F2 isoform that unleashes a metastatic program in melanoma.
Nat Commun. 2023 Apr 4;14(1):1867. doi: 10.1038/s41467-023-36967-2.
5
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
Cell. 2022 Jul 7;185(14):2591-2608.e30. doi: 10.1016/j.cell.2022.06.007.
6
Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis.
Cancer Discov. 2022 May 2;12(5):1314-1335. doi: 10.1158/2159-8290.CD-21-1006.
7
Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis.
Cancer Cell. 2020 Jan 13;37(1):55-70.e15. doi: 10.1016/j.ccell.2019.12.007.
8
Functional analysis of RPS27 mutations and expression in melanoma.
Pigment Cell Melanoma Res. 2020 May;33(3):466-479. doi: 10.1111/pcmr.12841. Epub 2019 Nov 22.
9
Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
J Invest Dermatol. 2019 Feb;139(2):430-438. doi: 10.1016/j.jid.2018.07.031. Epub 2018 Aug 24.
10
Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.
Mol Cell. 2017 Nov 16;68(4):731-744.e9. doi: 10.1016/j.molcel.2017.11.004.
本文引用的文献
1
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research.
Am J Transl Res. 2009;1(1):35-43. Epub 2009 Jan 1.
2
Nestin expression--a property of multi-lineage progenitor cells?
Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22. doi: 10.1007/s00018-004-4144-6.
3
Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution.
Int J Cancer. 2004 Jan 1;108(1):57-65. doi: 10.1002/ijc.11558.
4
Germline splicing mutations of CDKN2A predispose to melanoma.
Oncogene. 2003 Sep 25;22(41):6387-94. doi: 10.1038/sj.onc.1206736.
5
CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Oncogene. 2003 Jul 10;22(28):4444-8. doi: 10.1038/sj.onc.1206564.
6
Molecular abnormalities in lung cancer.
J Clin Oncol. 1998 Mar;16(3):1207-17. doi: 10.1200/JCO.1998.16.3.1207.
7
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens.
Br J Cancer. 1996 Jul;74(2):194-9. doi: 10.1038/bjc.1996.337.
8
Nonrandom chromosome changes in malignant melanoma.
Cancer Res. 1983 Oct;43(10):5010-6.
9
Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells.
Int J Cancer. 1990 Jun 15;45(6):1151-8. doi: 10.1002/ijc.2910450627.
10
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype.
Oncogene. 1992 Nov;7(11):2315-21.
Zotero 插件